Formulary management is the process health plans and institutions use to decide which prescription drugs they will cover, how much patients pay for them, and under what conditions they can be prescribed. It’s far more than a simple list of approved medications. A formulary is an entire system designed to balance two goals: ensuring patients get safe, effective treatment while keeping costs sustainable for both the plan and its members.
The system touches nearly every prescription you fill. It determines whether your medication is covered, what your copay looks like, and whether your doctor needs to get approval before prescribing it. Understanding how it works helps explain why two drugs that treat the same condition can have wildly different out-of-pocket costs.
How Drugs Get on the List
The central decision-making body in formulary management is the Pharmacy and Therapeutics (P&T) committee. This group of physicians, pharmacists, and other clinicians reviews the available evidence on a drug’s safety, effectiveness, and cost before deciding whether to add it to the formulary. In Medicare programs, the committee must include at least one independent practicing physician and one independent practicing pharmacist, both free of financial ties to drug manufacturers, pharmacy benefit managers, or anyone else who might profit from a formulary decision.
When a new drug is submitted for consideration, the committee evaluates the quality of the clinical evidence supporting it, often using standardized grading systems to assess how strong that evidence actually is. The core principle is straightforward: clinical value comes first. A drug’s safety profile and how well it works for patients take priority over everything else. But when two drugs perform similarly in clinical trials, cost becomes the tiebreaker.
Many organizations also use scoring tools to prioritize which drugs even warrant a full evaluation. If a medication clearly offers no advantage over what’s already on the formulary, it can be screened out early, saving the committee time for drugs that might genuinely improve patient care.
The Tier System and What You Pay
Most formularies organize drugs into tiers, each carrying a different level of cost-sharing. A drug on a lower tier costs you less out of pocket. While every plan structures its tiers differently, a common setup looks like this:
- Tier 1 (lowest copay): most generic drugs
- Tier 2 (medium copay): preferred brand-name drugs
- Tier 3 (higher copay): non-preferred brand-name drugs
- Specialty tier (highest copay): very high-cost drugs, often for complex conditions
This structure creates a financial incentive for patients and doctors to choose lower-tier options when they’re clinically appropriate. A generic cholesterol medication on Tier 1 might cost you $10, while a brand-name alternative on Tier 3 could run $60 or more for the same therapeutic effect. The tier a drug lands on isn’t random. It reflects a combination of clinical evaluation and the financial arrangements negotiated behind the scenes.
Utilization Management Tools
Beyond tiering, health plans use several tools to influence how and when certain drugs are prescribed. These are collectively called utilization management, and they add another layer of control to the formulary system.
Prior authorization requires your doctor to get preapproval from the insurer before a specific drug will be covered. This is common for expensive medications or drugs with significant safety concerns. Step therapy requires you to try a lower-cost or first-line treatment before the plan will cover a more expensive alternative. If the first drug doesn’t work or causes side effects, your doctor can then request the next option. Quantity limits cap how much of a medication you can get in a given prescription or time period, preventing overuse or stockpiling.
These tools are often a source of frustration for patients and doctors, but from the plan’s perspective, they serve a gatekeeping function: directing prescribing toward drugs with the strongest evidence and the best value, while reserving costlier options for situations where they’re genuinely needed.
How Rebates Shape the Formulary
One of the least visible but most influential forces in formulary management is rebate negotiation between health plans and drug manufacturers. Once a P&T committee determines that a drug has clinical value, the plan negotiates financial terms with the manufacturer. These rebates can significantly affect where a drug lands on the formulary.
The basic dynamic works like this: a manufacturer wants its drug to have preferred status on a formulary because that means more patients will use it. To earn that placement, the manufacturer offers the plan a rebate, essentially a discount on every prescription filled. The more favorable the formulary position, the larger the rebate the manufacturer is typically willing to offer. Conversely, if a competing drug is kept off the formulary entirely or placed in a non-preferred tier with higher copays, the remaining manufacturer will often negotiate a more generous rebate.
This can create situations that seem counterintuitive. A higher-cost drug might end up with a lower copay for patients than a cheaper alternative because the manufacturer offered a large enough rebate to offset the sticker price. The plan passes some of those savings through to members as lower out-of-pocket costs, which drives more prescriptions toward that drug and earns the plan even more rebate dollars. Market share rebates work on this exact principle: the manufacturer ties the rebate percentage to how much of the market its drug captures compared to competitors in the same class.
Protected Drug Classes
Not every therapeutic area gives plans full discretion over what to include. Medicare Part D requires plan sponsors to cover essentially all drugs in six protected categories: antidepressants, antipsychotics, anticonvulsants, immunosuppressants for transplant rejection, antiretrovirals (HIV medications), and cancer drugs. This rule exists because gaps in coverage for these conditions could cause serious, immediate harm to patients. Plans can still use tiering and some utilization management within these classes, but they cannot simply exclude a drug from coverage.
Outside of these protected classes, plans have considerably more flexibility. They can limit coverage to just one or two drugs in a therapeutic category, require step therapy through multiple alternatives, or exclude certain medications altogether.
How Biosimilars Are Changing Formularies
Biosimilars, which are near-copies of expensive biologic drugs, are becoming a major focus of formulary management as plans look for ways to control specialty drug spending. How quickly a biosimilar gains traction depends heavily on formulary decisions rather than just regulatory approval.
A clear example comes from Semglee, a biosimilar insulin. When employer-sponsored insurance plans began giving it preferred, unrestricted coverage, adoption surged. The share of employer plan members with unrestricted access to Semglee jumped from 8% to 48% between December 2021 and December 2022. Its market share in those plans went from under 1% throughout 2021 to nearly 19% by the end of 2022. In Medicaid, where formulary coverage expanded more modestly, market share grew from around 5% to about 11% over the same period.
What’s notable is that state policies allowing pharmacists to substitute biosimilars at the pharmacy counter played, at most, a secondary role. The primary driver was the formulary coverage decision itself. When a plan puts a biosimilar in a preferred position, patients and doctors shift to it. When it sits in a non-preferred tier or carries restrictions, adoption stays flat regardless of what the law allows. This underscores just how powerful formulary placement is in shaping real-world prescribing behavior.
Why It Matters for You
Formulary management directly affects your access to medications and what you pay for them. If your doctor prescribes a drug that’s not on your plan’s formulary, you may pay the full retail price. If it’s on a higher tier, your copay could be two or three times what you’d pay for a preferred alternative. And if your plan requires prior authorization or step therapy, there may be delays before you can start a new medication.
Formularies also change. Plans typically update their drug lists at least once a year, and sometimes more frequently when new drugs launch or rebate contracts shift. A medication that was preferred last year might move to a higher tier this year, changing your costs without any change in your health. Checking your plan’s current formulary before open enrollment, or whenever your doctor suggests a new prescription, can help you anticipate what you’ll actually pay at the pharmacy counter.